Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B.

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, Mass.

Novartis announced that it has agreed to terms to acquire Anthos Therapeutics for an upfront payment of $925 million. The deal will include abelacimab, a Factor XI-inhibiting monoclonal antibody in ...

Novartis announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage ...

Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for up to US$3.1 billion. Anthos was founded by Blackstone Life Sciences and ...

The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation ...

Novartis has gone full circle with Anthos Therapeutics. The Swiss pharma giant is doubling down on its expertise in the cardiovascular area by acquiring the clinical-stage biotech firm mostly owned by ...

Novartis agreed to acquire Blackstone Life Sciences' Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company retakes ...

Novartis NOVN0.11%increase; green up pointing triangle said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

the development and commercialization of Anthos Therapeutics’ product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in ...